These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Diagnostic and prognostic significance of plasma N-terminal-pro-brain natriuretic peptide in decompensated heart failure with preserved ejection fraction.
    Author: Paul B, Soon KH, Dunne J, De Pasquale CG.
    Journal: Heart Lung Circ; 2008 Dec; 17(6):497-501. PubMed ID: 18722158.
    Abstract:
    BACKGROUND: Preserved ventricular function is increasingly recognised in CHF. Although, NTpro-BNP is a well-established diagnostic marker in heart failure with impaired EF, its significance in heart failure with preserved EF is unclear. NT pro-BNP is secreted from the ventricular wall and plasma levels correlate to ventricular function. This study sought to determine the diagnostic and prognostic significance of plasma NTpro-BNP in patients with preserved EF heart failure. METHODS: We recruited 133 consecutive patients with decompensated HF. The primary end point was death or hospital readmission. RESULTS: Median (IQR) NTpro-BNP level at admission was elevated at 5043 ng/L (2693-10,784) and was significantly lower in preserved EF, 3569 ng/L (1707-6340) than in impaired EF, 6363 ng/L (3648-13,250) (P=0.001). Eight (6%) and 19 (14%) patients died after 1 and 6 months, respectively. In a regression analysis, worsening of NTpro-BNP levels after treatment was not predictive of mortality in heart failure with preserved EF (P=0.83). Levels at discharge correlated with readmission rates at 6 months in both groups, i.e. impaired (P=0.03) and preserved EF (P=0.02). CONCLUSION: NTpro-BNP is a reliable diagnostic marker of decompensation. However, in preserved EF heart failure, the plasma levels are significantly lower and a worsening in levels after treatment is not predictive of mortality.
    [Abstract] [Full Text] [Related] [New Search]